Drew Deniger - Mar 29, 2022 Form 3 Insider Report for Alaunos Therapeutics, Inc. (TCRT)

Role: VP, Research & Development
Signature: /s/ Drew Deniger
Stock symbol: TCRT
Transactions as of: Mar 29, 2022
Transactions value $: $0
Form type: 3
Date filed: 4/8/2022, 04:30 PM
Next filing: Sep 19, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TCRT	Common Stock						15K	Mar 29, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TCRT	Employee Stock Option (right to buy)							Mar 29, 2022	Common Stock	50K	$4.13	Direct	F1
holding	TCRT	Employee Stock Option (right to buy)							Mar 29, 2022	Common Stock	30K	$4.72	Direct	F2
holding	TCRT	Employee Stock Option (right to buy)							Mar 29, 2022	Common Stock	75K	$2.82	Direct	F3
holding	TCRT	Employee Stock Option (right to buy)							Mar 29, 2022	Common Stock	35K	$4.31	Direct	F4
holding	TCRT	Employee Stock Option (right to buy)							Mar 29, 2022	Common Stock	250K	$1.50	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on September 24, 2019. One-fourth of the shares underlying the option vested on September 24, 2020, and the remainder vests in twelve successive equal quarterly installments measured from September 24, 2020, subject to the Reporting Person's continued service through each such date.
F2	The option was granted on December 31, 2019. One-twelfth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.
F3	The option was granted on January 4, 2021. One-twelfth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.
F4	The option was granted on March 4, 2021. One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after December 31, 2020, subject to the Reporting Person's continued service through each such date.
F5	The option was granted on October 29, 2021. One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.